Table 1

Performance of the classifier. Performance of the 13 clusters classifier algorithm re-training and validation on the separate institutional populations using both leave-one-out and multiple 10-fold cross-validations.

Training set (total/events)

Validation set (total/events)

Hazard ratio (95%CI)

Log rank p value

Distant Metastases Free Survival for low risk group only#


DMFS at 3 years

DMFS at 5 years

DMFS at 10 years


OXFT (99/19)

KIT/GUYT(156/48)

2.17 (1.2–3.91)

<0.00001

91%

87%

79%

KIT (69/20)

OXFT/GUYT (186/47)

4.07 (2.23–7.41)

<0.00001

96%

92%

88%

GUYT (87/28)

OXFT/KIT (168/39)

5.93 (3.0–11.75)

<0.00001

93%

89%

82%

KIT/GUYT (156/48)

OXFT (99/19)

14.59 (5.38–39.5)

<0.00001

97%

94%

91%

OXFT/GUYT (186/47)

KIT (69/20)

3.44 (1.36–8.67)

0.005

96%

92%

84%

OXFT/KIT(168/39)

GUYT (87/28)

2.23 (1.05–4.71)

0.03

96%

92%

84%

Leave-one-out cross validation (255/67)*

3.86 (2.32–6.41)

<0.0001

94%

91%

84%

Multiple 10-fold cross-validation (255/67)

3.23 (2.66–3.84)

<0.0001

94%

90%

83%


# as estimated by Kaplan Meier survival curves.

Patients samples obtained from: OXFT: John Radcliffe Hospital, Oxford, UK; KIT Uppsala University hospital, Uppsala, Sweden; GUYT Guys hospital, London, UK.

• Reported results.

Loi et al. BMC Genomics 2008 9:239   doi:10.1186/1471-2164-9-239

Open Data